sábado, 7 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

The Download: a secretive antiaging drug and joining virtual power plants

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: a secretive antiaging drug and joining virtual power plants Date: 2026-08-28 12:35 Source: https://www.technologyreview.com/2026/08/28/1143113/the-download-antiaging-drug-joining-virtual-power-plants/ <p><em>This is today’s edition of </em><a href="https://forms…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Generation Lab's treatment blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism, and restores health and youth to multiple tissues.

    60% confidence

  • Irina Conboy says she has found a combination of two existing drugs that can produce youthful effects without the need for any bodily fluid exchange.

    60% confidence

  • OpenAI's Codex agent could continue tasks until it's 'put to sleep' and generate follow-up tasks without prompting.

    60% confidence

  • A torrent of AI-generated study papers written by fake researchers is contaminating academic publishing, quietly haunting the academic record.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,996
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,996 factos verificados com a fonte5,552 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
The Download: a secretive antiaging drug and joining virtual power plants — Source | Via News | pt.VIA.NEWS